Tractament del CPNM metastàtic en primera i segona línia amb immunoteràpia: informe d'avaluació de resultats
Abstract
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of LC for 2019 was 29,503 new cases. LC remains the leading cause of cancer death in Spain in both sexes, with an overall five-year survival of 13%, which decreases to 1% in the metastatic stage. Non-small cell lung cancer (NSLC) accounts for approximately 80% - 90% of all LC and is classified according to histology into adenocarcinoma (≈ 40%), large cell carcinoma (15%), and scaly or squamous cell carcinoma (≈ 25-30%). In general, it differs between the non-scathose histology (adenocarcinoma and large cell carcinoma) and scathose one.
Keywords
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Tractament del CPNM metastàtic en primera i segona línia amb immunoteràpia: informe d'avaluació de resultats. Barcelona: Servei Català de la Salut; 2021.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/6198This item appears in following collections
The following license files are associated with this item: